Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
TTX-030, nab-paclitaxel and gemcitabine · 1 trial · 1 indication
PFS is defined as the time from randomization until first documentation of progression or death from any cause, whichever occurs first
| Arm | Type | Description |
|---|---|---|
| Arm 1 | EXPERIMENTAL | TTX-030 plus nab-paclitaxel and gemcitabine |
| Arm 2 | EXPERIMENTAL | TTX-030 plus budigalimab plus nab-paclitaxel and gemcitabine |
| Arm 3 | ACTIVE_COMPARATOR | Nab-Paclitaxel and gemcitabine |
| Name | Type | Description |
|---|---|---|
| TTX-030, nab-paclitaxel and gemcitabine | COMBINATION_PRODUCT | Dose and schedule per protocol |
| TTX-030, budigalimab, nab-paclitaxel and gemcitabine | COMBINATION_PRODUCT | Dose and schedule per protocol |
| Nab-Paclitaxel and gemcitabine | COMBINATION_PRODUCT | Dose and schedule per protocol |
Abbreviated Inclusion Criteria: 1. Age 18 years or older, is willing and able to provide informed consent 2. Histologically or cytologically confirmed diagnosis of metastatic PDAC. 3. No prior systemic treatment for metastatic disease. 4. Evidence of measurable disease per RECIST 1.1. 5. Appropriat...
Top 20 of 67 competitors
TTX-030 is an investigational small molecule being studied for the treatment of solid tumors, including pancreatic cancer. It is being evaluated in combination with immunotherapy and/or chemotherapy in adult patients with advanced cancers. The drug is currently in clinical development and has not been approved by regulatory authorities.
TTX-030 is a small molecule that targets CD39, an enzyme involved in the adenosine pathway that can suppress immune responses in tumors. By inhibiting CD39, TTX-030 aims to enhance the body's immune system to fight cancer cells. This mechanism is being studied in combination with other therapies for solid tumors.
TTX-030 is being developed by AbbVie Inc., a biopharmaceutical company listed on the New York Stock Exchange under the ticker symbol ABBV. AbbVie is conducting clinical trials to evaluate the safety and efficacy of TTX-030 in patients with advanced cancers, including pancreatic cancer.
TTX-030 is in Phase 1 and Phase 2 clinical trials. A Phase 1 study (NCT04306900) has been completed, and a Phase 2 study (NCT06119217) is active but not recruiting patients. The drug is investigational and has not received FDA approval for any indication.
TTX-030 has been studied in two clinical trials. NCT04306900 is a completed Phase 1 trial evaluating TTX-030 in combination with immunotherapy and/or chemotherapy in adults with advanced solid tumors. NCT06119217 is an active Phase 2 trial studying TTX-030 with chemotherapy, with or without budigalimab, in patients with pancreatic cancer.
No, TTX-030 and budigalimab are different drugs. TTX-030 is a small molecule targeting CD39, while budigalimab is an immunotherapy agent. They are being studied together in combination with chemotherapy for the treatment of pancreatic cancer, as seen in the Phase 2 trial NCT06119217.